Evidence map›Paper›PMID 24611672›Full record

ArticleTransfusion2014

Mean remaining life span: a new clinically relevant parameter to assess the quality of transfused red blood cells.

Denison J Kuruvilla, Demet Nalbant, John A Widness, Peter Veng-Pedersen

Abstract read
In one paragraph

Article in Transfusion, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Models for the red blood cell lifespan.Journal of pharmacokinetics and pharmacodynamics · 2016
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Denison J KuruvillaDepartment of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa.
Demet Nalbant
John A Widness
Peter Veng-Pedersen

Funding

THE RoLE OF NEONATAL ANEMIA IN LEARNING AND MEMORYP01HL046925 · NHLBI · UNIVERSITY OF IOWA · PI SOLA-VISNER, MARTHA C. · 1992 to 2022
$34.3M
NHLBI NIH HHS 2 P01-HL046925NHLBI NIH HHS P01 HL046925
6 · The paper itself

Abstract

backgroundThe quality of transfused red blood cells (RBCs) to treat anemia depends on its potential for oxygen delivery, governed by two properties: 1) initial posttransfusion recovery and 2) life span of initially surviving RBCs. The latter property is poorly evaluated by the traditional mean potential life span (MPL) or mean cell age (MA), because these parameters do not evaluate how long transfused RBCs remain in circulation. Furthermore, evaluation of MPL is based on two problematic assumptions regarding transfused RBCs: 1) they were produced at a constant steady-state rate and 2) they have similar storage life spans. STUDY DESIGN AND

methodsThis work introduces a new parameter, the mean remaining life span (MRL) to quantify transfused RBC survival (TRCS) and presents a simple algorithm for its evaluation. The MRL was calculated for four adult subjects with sickle cell disease and four adult diabetic and nondiabetic subjects using RBC survival data sets with existing TRCS parameters.

resultsThe RBC survival curves in the sickle cell subjects were nonlinear with rapid decline in survival within the first 5 days. The MRL was approximately 4.6 days. Thus, the MRL was indicative of the survival of all transfused RBCs. For the diabetic and nondiabetic subjects, the RBC disappearance curves did not deviate substantially from a linear decline. Thus, the estimates for MRL ranging from 39 to 51 days are similar to the MA previously computed.

conclusionMRL overcomes limitations of previously proposed TRCS parameters, is simpler to calculate, and is physiologically and clinically more appropriate.

Indexed as

Models, TheoreticalQuality Assurance, Health CareAdultAlgorithmsAnemia, Sickle CellBlood BankingBlood BanksBlood PreservationBlood TransfusionCell SurvivalDiabetes MellitusErythrocytesHumans

Identifiers

PMID24611672
PMCPMC4404519

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.